Related Experiment Video
Updated: Jun 2, 2026
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
18F-FDG PET/CT for predicting major pathological response to neoadjuvant therapy in non-small cell lung cancer: a
Yaoyu Wu1, Boxiao Hu1, Dazhi Liu1
1Department of Thoracic Surgery, Northern Theater General Hospital, Shenyang, Liaoning, China.
Objective:
To comprehensively evaluate the diagnostic utility of metabolic parameter changes on 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) for predicting pathological response after neoadjuvant therapy in patients with non-small cell lung cancer (NSCLC).
Methods:
The Cochrane Library, Web of Science, Embase, and PubMed were comprehensively retrieved up until October 2024 to identify diagnostic test accuracy studies evaluating the predictive efficacy of 18F-FDG PET/CT for postoperative pathological response in NSCLC patients following neoadjuvant therapy. Two independent reviewers screened studies, collected information, and evaluated the risk of bias. Statistical analysis was conducted via Meta-Disc 1.4 and Stata 17.0 software.
Results:
Fourteen eligible investigations encompassing 1,315 subjects were incorporated. The findings revealed that for predicting major pathological response (MPR) after neoadjuvant therapy, the metabolic parameter ΔSUVmax% on 18F-FDG PET/CT achieved an area under the summary receiver operating characteristic curve (sAUC) of 0.96 (95% CI: 0.94-0.97), with pooled sensitivity and specificity of 0.87 (0.73-0.94) and 0.93 (0.84-0.97), respectively. Similarly, the parameter SUVmax itself yielded an sAUC of 0.95 (0.93-0.96), with sensitivity of 0.80 (0.63-0.91) and specificity of 0.94 (0.87-0.97). Stratified analyses indicated that the neoadjuvant treatment regimen (single-modality vs. combination therapy), the cut-off value (<55% vs. ≥55%), sample size (<40 vs. ≥40), and the proportion of adenocarcinoma in the study sample (<40% vs. ≥40%) were potential sources of heterogeneity.
Conclusion:
Quantitative metabolic metrics derived from 18F-FDG PET/CT (ΔSUVmax% and SUVmax) demonstrate high diagnostic performance for pathological response after neoadjuvant therapy in NSCLC. These metrics may serve as noninvasive adjunct tools for response assessment, supporting individualized neoadjuvant strategies and facilitating clinical trial design in the perioperative immunotherapy era. However, given the limited number and quality of the available studies, these findings require confirmation through high-quality research.
Systematic Review Registration:
https://www.crd.york.ac.uk/prospero/, identifier CRD42024612056.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
06:53Management of Respiratory Motion Artefacts in 18F-fluorodeoxyglucose Positron Emission Tomography using an Amplitude-Based Optimal Respiratory Gating Algorithm
Published on: July 23, 2020